UNTITLED

被引：2

作者：

ARANKO, K

HANHIJARVI, H

HUMPHREYS, M

DRAKE, J

LAWTON, WA

机构：

[1] LEIRAS OY,R&D,SF-20101 TURKU,FINLAND

[2] BOEHRINGER INGELHEIM LTD,MED OPERAT,BRACKNELL RG12 8YS,BERKS,ENGLAND

[3] BOEHRINGER INGELHEIM LTD,BIOSTAT & DATA MANAGEMENT,BRACKNELL RG12 8YS,BERKS,ENGLAND

来源：

BONE | 1995年 / 16卷 / 02期

关键词：

D O I：

10.1016/8756-3282(95)90127-2

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：275 / 276

页数：2

共 8 条

[1]

CANFIELD RE, 1987, BONE S1, V8, P557

[2]

ELOMAA I, 1985, LANCET, V1, P1155

[3]

BISPHOSPHONATES - PHARMACOLOGY AND USE IN THE TREATMENT OF TUMOR-INDUCED HYPERCALCEMIC AND METASTATIC BONE-DISEASE [J].

FLEISCH, H .

DRUGS, 1991, 42 (06) :919-944

[4]

FLEISCH H, 1993, BISPHOSPHONATES BONE, P50

[5]

RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL OF CLODRONATE IN MULTIPLE-MYELOMA [J].

LAHTINEN, R ;

LAAKSO, M ;

PALVA, I ;

VIRKKUNEN, P ;

ELOMAA, I .

LANCET, 1992, 340 (8827) :1049-1052

[6]

DOUBLE-BLIND CONTROLLED TRIAL OF ORAL CLODRONATE IN PATIENTS WITH BONE METASTASES FROM BREAST-CANCER [J].

PATERSON, AHG ;

POWLES, TJ ;

KANIS, JA ;

MCCLOSKEY, E ;

HANSON, J ;

ASHLEY, S .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :59-65

[7]

PENTIKAINEN PJ, 1989, INT J CANCER PHARM T, V27, P122

[8]

1989, EC NOTE GUIDANCE INV, V3, P54

← 1 →